Articles published by Melinta Therapeutics, LLC

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

August 07, 2025

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Joins NHIA Future of Infusion Advisory Council

December 02, 2024

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products

October 16, 2024

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer

September 05, 2024

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces the Appointment of Fabrizio Tondolo, MD, as Vice President of Medical Affairs

August 06, 2024

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris

May 23, 2024

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID

December 05, 2023

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023

October 11, 2023

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection)

July 31, 2023

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens

July 10, 2023

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada

May 15, 2023

From Melinta Therapeutics, LLC

Via Business Wire

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

March 22, 2023

From Melinta Therapeutics, LLC

Via Business Wire

Tickers CDTX

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

January 25, 2023

From Melinta Therapeutics, LLC

Via Business Wire

Tickers CDTX

Melinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes Event

November 30, 2022

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022

October 18, 2022

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.

July 27, 2022

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics

April 06, 2022

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs

March 14, 2022

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio

January 06, 2022

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development

October 25, 2021

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy

July 06, 2021

From Melinta Therapeutics, LLC

Via Business Wire

Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer

June 29, 2021

From Melinta Therapeutics, LLC

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.